Currently, only corticosteroids and tocilizumab (TCZ, an IL-6 receptor antagonist that blocks IL-6-mediated signal transduction by inhibiting IL-6 binding to IL-6 receptor and is the only FDA-approved therapy for treating CART-cell-associated CRS (Si and Teachey, 2020)) are recommended by many national and international guidelines for the management of CRS (Santomasso et al., 2021; Hayden et al., 2022). Here, IL6 is linked to congenital rubella syndrome.